文献速递胸部肿瘤放疗放疗物理与技术

肺癌光子与质子放疗中解剖变化对剂量和NTCP的影响及重计划获益

Effects of anatomical changes on dose and normal tissue complication probabilities and the benefit of replanning in photon and proton therapy of lung cancer patients.
PubMed 文献 · Radiother Oncol · 2025-07-26

本研究纳入83例存在解剖变化的肺癌患者,分别对光子与质子治疗在计划CT上制定计划、在重复CT上重算剂量并重计划,评估临床剂量与NTCP标准。无或轻微解剖变化患者剂量通过率为光子89%、质子64%,肿瘤退缩者为83%、52%,肺不张或胸腔积液者仅24%、14%。重计划显著获益者光子为7/53(13%)、质子为6/35(17%),肿瘤退缩者NTCP改善最明显。

要点

  • 肺不张或胸腔积液患者必须考虑自适应放疗,剂量通过率仅24%(光子)和14%(质子)。
  • 无或轻微解剖变化患者多数无需重计划,剂量通过率光子89%、质子64%。
  • 肿瘤退缩患者重计划有适度NTCP获益,质子治疗剂量与NTCP获益略大于光子。

核心结论

  • 自适应放疗并非对所有肺癌患者都有益或必需,但对肺不张或胸腔积液患者是必要的。
  • 肿瘤退缩患者重计划显示适度的NTCP获益,质子治疗的剂量与NTCP获益略大于光子治疗。

研究设计与样本

  • 研究纳入83例存在解剖变化的肺癌患者,对光子和质子治疗分别在计划CT上制定计划、在重复CT上重算剂量并重计划。
  • 随后按临床剂量标准(靶区覆盖和危及器官最大剂量)和NTCP标准进行评估。

主要发现

  • 无或轻微解剖变化患者剂量评估通过率光子为89%、质子为64%。
  • 肿瘤退缩患者剂量评估通过率光子为83%、质子为52%。
  • 肺不张或胸腔积液患者剂量评估通过率光子为24%、质子为14%。
  • 剂量评估通过的患者中,NTCP评估失败光子为3/53(6%)、质子为4/53(11%)。
  • 重计划显著获益患者光子为7/53(13%)、质子为6/35(17%),肿瘤退缩者NTCP改善最明显。

关键数值与推荐

  • 剂量评估标准包括靶区覆盖和危及器官最大剂量。
  • NTCP评估标准依据正常组织并发症概率。

临床怎么用

  • 对肺不张或胸腔积液患者应积极考虑自适应放疗重计划。
  • 对无或轻微解剖变化患者可较少依赖重计划。
  • 肿瘤退缩患者可评估重计划的NTCP获益,质子治疗可能获益略大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Adaptive radiotherapy (ART) protocols are very labor-intensive and the clinical relevance regarding treatment outcome is not always evident. Therefore, the added value of replanning should be investigated. In this study, the effects of anatomical changes on dose and normal tissue complication probability (NTCP) and the benefits of replanning were investigated for photon and proton therapy in lung cancer patients. MATERIALS AND METHODS: In 83 lung cancer patients with anatomical changes, a treatment plan on the planning CT, and a dose recalculation and replanning on a repeat CT was performed for both photon and proton therapy and subsequently evaluated for clinical dose (target coverage and organ-at-risk maximum dose) and NTCP criteria. RESULTS: The percentage of patients passing the dose evaluation for photons/protons were 89 %/64 % for patients with no or minimal anatomical changes, 83 %/52 % for patients with tumor regression, and 24 %/14 % for patients with atelectasis or pleural effusion. In patients that passed the dose evaluation, the NTCP evaluation failed in 3/53 (6 %) of photon plans and 4/53 (11 %) of proton plans. The number of patients that benefitted substantially from replanning was 7/53 (13 %) for photons and 6/35 (17 %) for protons, with the most evident NTCP improvements in patients with tumor regression. CONCLUSION: ART is not beneficial and required for all patients. However, it is necessary for patients with atelectasis or pleural effusion. ART shows modest NTCP benefits in patients with tumor regression. The dose and NTCP benefits are slightly larger in patients receiving proton therapy compared to photon therapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hattu D, Taasti VT, Emans D, et al. Effects of anatomical changes on dose and normal tissue complication probabilities and the benefit of replanning in photon and proton therapy of lung cancer patients. Radiother Oncol. 2025. PMID: 40721092. doi:10.1016/j.radonc.2025.111063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。